BrainStorm Cell ALS Candidate Shows Benefit In Patients With Less Severe Disease

BrainStorm Cell Therapeutics Inc BCLI has announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research Symposium.
The NurOwn technology platform (autologous MSC-NTF cells) represents an investigational therapeutic approach to targeting disease pathways critical in neurodegenerative disorders.
The Phase 3 trial did not reach statistical significance on the primary and secondary endpoints in the patients of Amyotrophic lateral sclerosis (ALS).
But the new data showed that NurOwn treatment could be potentially beneficial in a subset of participants with less severe disease.
In the subgroup of participants predicted to have long to very long survival, NurOwn treated participants had a more significant percentage of responders than placebo (33% vs. 14%).
In the pre-specified subgroup of participants with ALS Functional Rating Scale greater than or equal to 35 at baseline, NurOwn had a greater percentage of responders than placebo (34.6% versus 15.6%).
Price Action: BCLI shares are down 3.21% at $3.62 during the market session on the last check Monday.